Frankfurt am Main, February 25, 2025 – PARMANTIER & CIE. has updated its coverage of CLINUVEL Pharmaceuticals Ltd. (ASX: CUV - ADR Level1: CLVLY – Frankfurt/M Stock Exchange: UR9 - ISIN: AU000000CUV3). CLINUVEL has adjusted its corporate strategy at the turn of 2024 to focus on targeted expansion and accelerated development processes. By concentrating on key projects in clinical development, the company aims to significantly enhance both market penetration and enterprise value.
Despite a challenging macroeconomic environment, CLINUVEL has demonstrated positive operational developments following this realignment. The corporate strategy emphasizes the further development of SCENESSE® therapy for vitiligo, ACTH, and EPP, while deprioritizing less advanced projects. Furthermore, the introduction of the "PhotoCosmetics" product line represents a significant expansion of the business model. The market launch of CYACÊLLE Radiant is scheduled for 2025, with additional product lines to follow from 2026. This expansion into the non-pharmaceutical segment is expected to unlock further growth potential. Our full research report on the latest developments of CLINUVEL Pharmaceuticals is available at: Bloomberg/parmantiercie; Short code: {DS FMG <GO>} PARMANTIER & Cie. Research https://www.parmantiercie.com/research About PARMANTIER & CIE. GmbH: PARMANTIER & CIE. specializes in advising and facilitating corporate financing solutions, including equity, debt, and hybrid financing, following the approach of a classic merchant bank. The firm invests in both publicly traded and private companies, combining the traditional values of honorable business conduct with innovative financing solutions tailored for a dynamic economic landscape. By actively engaging with its own capital, PARMANTIER & CIE. takes independent paths and provides customized financial solutions for both listed and private companies. Contact: PARMANTIER & Cie. GmbH info@parmantiercie.com End of Media Release Issuer: Parmantier & Cie. GmbH Key word(s): Finance
10.02.2025 CET/CEST Dissemination of a Press Release, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Parmantier & Cie. GmbH |
Neue Mainzer Str. 66-68 | |
60311 Frankfurt | |
Germany | |
Internet: | https://www.parmantiercie.com |
EQS News ID: | 2083763 |
End of News | EQS Media |
|
2083763 10.02.2025 CET/CEST
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.